02360nam 22004813 450 991096417220332120251121193706.01-58528-581-1(CKB)4100000004827102(MiAaPQ)EBC5412768(Au-PeEL)EBL5412768(OCoLC)1039079127(EXLCZ)99410000000482710220251121d2018 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierBiosimilars and Biologics Implementation and Monitoring in a Health Care Setting1st ed.Bethesda :American Society of Health-System Pharmacists,2018.©2018.1 online resource (192 pages)1-58528-580-3 A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies.Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars are finally beginning to exert a greater impact on practice. ASHP's Biosimilars & Biologics: Implementation and Monitoring in a Healthcare Setting is an authoritative, evidence-based resource that provides an in-depth perspective on all areas related to these innovative drugs.Biosimilars and Biologics Biosimilar PharmaceuticalsDrug CompoundingDrug MonitoringBiosimilar Pharmaceuticals.Drug Compounding.Drug Monitoring.615.1/9Lucio Steven1857926MiAaPQMiAaPQMiAaPQBOOK9910964172203321Biosimilars and Biologics4459071UNINA